Long-term follow-up of venlafaxine in treatment-resistant major depression: A Canadian multicentre open-label trial

1998 ◽  
Vol 8 ◽  
pp. S156
Author(s):  
D. Bakish ◽  
P.H. Silverstone ◽  
C. de Montigny
Keyword(s):  
Major Depression ◽  
Treatment Resistant ◽  
Open Label ◽  
Long Term Follow Up ◽  
Open Label Trial

scholarly journals Long-term follow-up in an open-label trial of triheptanoin in GLUT1 deficiency syndrome: a sustained dramatic effect

2019 ◽  
Vol 90 (11) ◽  
pp. 1291-1293 ◽  
Author(s):  
Elodie Hainque ◽  
Domitille Gras ◽  
Aurélie Meneret ◽  
Mariana Atencio ◽  
Marie-Pierre Luton ◽  
...  
Keyword(s):  
Deficiency Syndrome ◽  
Open Label ◽  
Dramatic Effect ◽  
Glut1 Deficiency ◽  
Glut1 Deficiency Syndrome ◽  
Long Term Follow Up ◽  
Open Label Trial

An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression

2004 ◽  
Vol 161 (1) ◽  
pp. 171-174 ◽  
Author(s):  
Carlos A. Zarate ◽  
Jennifer L. Payne ◽  
Jorge Quiroz ◽  
Jonathan Sporn ◽  
Kirk K. Denicoff ◽  
...  
Keyword(s):  
Major Depression ◽  
Treatment Resistant ◽  
Open Label ◽  
Open Label Trial

THUR 173 Longterms: 10-year experience of fingolimod in RRMS patients

2018 ◽  
Vol 89 (10) ◽  
pp. A22.3-A22
Author(s):  
Cohen Jeffrey ◽  
Tenenbaum Nadia ◽  
Bhatt Alit ◽  
Pimentel Ron ◽  
Kappos Ludwig
Keyword(s):  
Adverse Events ◽  
Safety Profile ◽  
Brain Volume ◽  
Disability Progression ◽  
Open Label ◽  
T2 Lesions ◽  
Long Term Follow Up ◽  
Efficacy Measures

ObjectivesPresent results for up to 10 years of fingolimod treatment in RRMS patients.MethodsLONGTERMS is an open-label, single-arm, extension study evaluating the long-term safety, tolerability and efficacy of fingolimod in patients who previously participated in earlier fingolimod studies. Key efficacy measures: annualised relapse rate (ARR), proportion of patients free of 6 month confirmed disability progression (6 m-CDP), annualised rate of new or newly enlarging T2 lesions (ARneT2), and annualised rate of brain atrophy (ARBA). Safety analyses: adverse events (AEs) and serious AEs (SAEs) frequencies.Results3168 patients were included in the analysis. ARR decreased with longer exposure from 0.26 (Month [M] 0–12) to 0.20 (M0–60) and 0.19 (M0–120). Most patients remained free from 6 m-CDP at M60 (79.3%) and M120 (68.1%). ARneT2 decreased from 1.31 (M0–12) to 0.90 (M0–60), and 0.71 (M0–120). Change in brain volume was stable throughout the study (−0.37 [M12], −0.33 [M60] and −0.32 [M120]). Long-term exposure did not raise new safety concerns. No increase in frequencies of AEs or SAEs per year was observed over long-term fingolimod treatment.ConclusionsLong-term follow-up confirmed the established safety profile of fingolimod. Treatment was associated with a sustained low level of disease activity as expressed by clinical and MRI outcomes.DisclaimerPreviously presented at ECTRIMS 2017

Sign in / Sign up

Export Citation Format

Share Document